Genome-wide association studies: how predictable is a person’s cancer risk?

  title={Genome-wide association studies: how predictable is a person’s cancer risk?},
  author={Dimitrios H. Roukos},
  journal={Expert Review of Anticancer Therapy},
  pages={389 - 392}
  • D. Roukos
  • Published 1 April 2009
  • Biology
  • Expert Review of Anticancer Therapy
From overenthusiasm to scientific assessment and hard reality, the time required for this transiton has recently been drastically shortened. As high-throughput screening technology is rapidly evolving, it allows for the testing of new conceptual study designs to manage highly complex diseases, such as cancer. Profiling the expression of thousands of genes simultaneously by microarrays created optimism a decade ago. It was thought that we could move away from an empirical, general, tumor–node… 

Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks

  • D. Roukos
  • Biology
    The Pharmacogenomics Journal
  • 2011
The necessity of molecular networks modeling to understand complex gene–gene, protein–protein and gene–environment interactions is discussed, and the potential of systems clinico-biological approaches to predict intracellular signaling pathways components networks and cancer heterogeneous cells within an individual tumor is described.

Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care

  • D. Roukos
  • Biology
    Expert review of molecular diagnostics
  • 2010
This clinico–genome systems model opens the way for the discovery of new molecular innovations, both predictive markers and therapies, towards personalized treatment of cancer, by integrating clinical and genetics data into reverse engineering-based network modeling to approach the extremely complex genotype–phenotype map.

Protein-altering germline mutations implicate novel genes related to lung cancer development

The findings implicate germline genetic variants in ATM with lung cancer susceptibility and suggest KIAA0930 as a novel candidate gene for lung cancer risk.

Novel clinico-genome network modeling for revolutionizing

This clinico–genome systems model, published for the first time, opens the way for the discovery of new molecular innovations, both predictive markers and therapies, towards personalized treatment of cancer.

Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice.

  • D. Roukos
  • Medicine, Biology
    Biomarkers in medicine
  • 2010
The intensive research effort for developing biomarkers could be chronologically classified into four fields: the use of traditional clinicopathologic features and environmental factors, including lifestyle, classic single-gene molecular research, preliminary genome-wide association studies and complete genome sequencing and molecular networks, which are currently being used.

Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks

How these new markers, added to current standard factors, could improve early breast cancer treatment decisions are evaluated, including age, tumor size, grade, hormone receptor status and HER2 status.

The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case–control studies

This meta-analysis confirms that XRCC3 rs1799794 is related to cancer risk, especially increased risk for breast cancer and thyroid cancer and reduced risk for ovarian cancer, however, well-designed large-scale studies are required to further evaluate the results.

CDH1 Testing: Can it Predict the Prophylactic or Therapeutic Nature of Total Gastrectomy in Hereditary Diffuse Gastric Cancer?

If the authors could identify high-risk individuals in the general population and subsequently tailor an effective preventive intervention, then they could protect them by saving their lives, and this achievement is now realistic, although it concerns a small only fraction of cases.

Challenges in Developing New Biomarkers for Breast Cancer

The study showed that 5-year distant disease-free survival was modestly improved when ER, PR, HER2, and Ki67 analysis of lymph node metastasis was considered in addition to standard primary tumor analysis, and confirmed the need to identify novel sophisticated biomarkers.



Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer.

  • D. Roukos
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
The 21-gene assay is a better recurrence predictor than the currently used Adjuvant!—a validated algorithm based on classical clinicopathologic features—and it can be used for tailoring chemotherapy among individual patients with hormone receptor (HR) –positive operable breast cancer.

Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention

  • D. Roukos
  • Biology, Medicine
    Expert review of molecular diagnostics
  • 2009
There has been an explosion in biomedical research for the identification of genetic variation-based personalized management of complex diseases and potential highly effective, risk-guided prevention strategies could dramatically reduce incidence and mortality of the disease.

Genome-wide association studies in cancer.

Genome-wide association studies have been conducted in five of the commonest cancer types and have identified more than 20 novel disease loci, confirming that susceptibility to these diseases is polygenic.

Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery

  • D. Roukos
  • Medicine, Biology
    Expert review of molecular diagnostics
  • 2008
Combining established classic and new risk factors, including familial BRCA susceptibility to breast cancer, an integrated surgery-guided algorithm for clinical validity is proposed, and future genome-wide association studies larger than those currently available using newer genotyping platforms with more than 1 million single-nucleotide polymorphisms and copy number variants will complete the genetic map.

Use of gene signatures to improve risk estimation in cancer.

This is one of the largest studies in human cancer showing the ability of gene expression profiles to improve risk stratification beyond established risk assessment algorithms that take into account clinicopathological variables.

Genome-wide association study identifies novel breast cancer susceptibility loci

To identify further susceptibility alleles, a two-stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls was conducted, followed by a third stage in which 30 single nucleotide polymorphisms were tested for confirmation.

Multiple newly identified loci associated with prostate cancer susceptibility

A genome-wide association study using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at ≤60 years or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (<0.5 ng/ml) identified seven loci associated with prostate cancer on chromosomes 3, 6, 7, 10, 11, 19 and X.

Multiple loci identified in a genome-wide association study of prostate cancer

The findings point to multiple loci with moderate effects associated with susceptibility to prostate cancer that, taken together, in the future may predict high risk in select individuals.

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer

Four SNPs in intron 2 of FGFR2 (which encodes a receptor tyrosine kinase and is amplified or overexpressed in some breast cancers) that were highly associated with breast cancer were identified and confirmed in 1,776 affected individuals and 2,072 controls from three additional studies.

Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes

Results from eight case-control groups demonstrate that this variant in TCF2 (HNF1β), a gene known to be mutated in individuals with maturity-onset diabetes of the young type 5, confers protection against type 2 diabetes.